An van Es-Johansson, M.D.

Dr. An van Es-Johansson has served on Savara’s Board of Directors since December 2019. Most recently, she was the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease. She currently serves on the Board of Directors at Plus Therapeutics, Inc., Lumos Pharma, Inc., IRLAB Therapeutics AB and the privately held company Agendia BV. Previously, Dr. van Es-Johansson served in a range of executive roles of increasing responsibility at Sobi, an international rare disease company headquartered in Stockholm, Sweden, including as Vice President and Head of EMENAR medical affairs for specialty care and partner products. Prior to her time at Sobi, Dr. van Es-Johansson served in leadership positions at large pharmaceutical and smaller biotechnology companies, including Roche, Eli Lilly, Active Biotech, and BioStratum. From 2004 to 2016 she was a member of the scientific advisory board for Uppsala BIO. Dr. van Es-Johansson received a M.D. from Erasmus University, Rotterdam, The Netherlands.